Daniluromer by Edesa Biotech for Contact Dermatitis: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Daniluromer overview

EB-01 is under development for the treatment of chronic allergic contact dermatitis. The therapeutic candidate is administered through the topical route. It is a non-steroidal anti-inflammatory molecule. It acts by targeting sPLA2 (secreted phospholipase A2).

Edesa Biotech overview

Edesa Biotech is a clinical-stage biopharmaceutical and healthcare company, that develops gastrointestinal and dermatological diseases, including alternatives to topical steroids. The company’s pipeline includes EB05, EB07, EB01, EB02 and EB06. Its pipeline candidates treat covid 19, systemic sclerosis, allergic contact dermatitis (ACD), hemorrhoids and vitiligo. Edesa Biotech technology includes novel monoclonal antibodies for immune and inflammatory diseases. It has operations in Canada and the US. Edesa Biotech is headquartered in Markham, Ontario, Canada.

For a complete picture of Daniluromer’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.